Patients The hidden access gap in Europe’s lung cancer hospital data New hospital-level analysis shows a provider landscape that is more concentrated, regionally uneven & strategically complex than commercially assumed.
News Jazz, Roche combo cleared by FDA for lung cancer Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
Oncology Innovation, real-world data, and precision medicine: Pierre ... Ahead of ASCO 2025, Pierre Fabre charts bold progress in NSCLC with targeted therapies, real-world data, and innovative partnerships
News CRUK scientists find new tool to test lung cancer therapies Researchers in the UK have developed a lung cancer cell line that they believe could be an important new tool for the discovery of new therapies.
News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.